Harvard Bioscience Inc (HBIO) Common Stock USD0.001

Sell:$0.34Buy:$0.48$0.01 (2.23%)

NASDAQ:1.26%
Market closed | Prices delayed by at least 15 minutes
Sell:$0.34
Buy:$0.48
Change:$0.01 (2.23%)
Market closed | Prices delayed by at least 15 minutes
Sell:$0.34
Buy:$0.48
Change:$0.01 (2.23%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.

Key people

James W. Green
Chairman of the Board, President, Chief Executive Officer
Mark Frost
Interim Chief Financial Officer, Treasurer
Bertrand Loy
Lead Independent Director
Katherine Anne Eade
Independent Director
Alan I. Edrick
Independent Director
Thomas W. Loewald
Independent Director
Click to see more

Key facts

  • EPIC
    HBIO
  • Location
    United States
  • Sector
    Technology
  • Industry
    Scientific & Technical Instr.
  • ISIN
    US4169061052
  • Market cap
    $17.60m
  • Employees
    330
  • Shares in issue
    44.21m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.